Misbadi (Dabigatran Etexilate)

Dabigatran etexilate is a prodrug that is converted in the body to dabigatran, which directly and reversibly binds to thrombin (factor IIa). This binding blocks thrombin’s ability to convert fibrinogen into fibrin, thereby inhibiting the formation and extension of blood clots throughout the vascular system.

The dose of Misbadi is individualized by the prescribing clinician based on the specific indication, the patient’s renal function, age, weight and any concomitant medications. Healthcare professionals determine the appropriate strength and dosing schedule, and patients should follow the prescriber’s instructions exactly.

Safety data for dabigatran etexilate in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and a healthcare provider should be consulted before use.

To place an order, submit an enquiry on the Misbadi product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Misbadi (dabigatran) is a direct thrombin inhibitor, whereas the traditional alternative warfarin is a vitamin K antagonist that requires routine INR monitoring. Compared with other DOACs such as rivaroxaban or apixaban, dabigatran offers a predictable anticoagulant effect and does not need regular lab testing, but it may have a higher risk of gastrointestinal bleeding in some patients.

Misbadi should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat. Do not store in the bathroom or near a kitchen sink, and keep out of reach of children.

Misbadi is taken orally, usually as a whole tablet swallowed with water. It can be taken with or without food, but patients should follow the prescriber’s guidance on timing relative to meals. The tablet should not be crushed, chewed, or split unless specifically instructed by a healthcare professional.

The most serious risks include major bleeding events such as gastrointestinal hemorrhage, intracranial bleeding, and life‑threatening hemorrhage in other organs. Patients should be alert for signs of unusual bruising, blood in urine or stool, severe headache, or sudden weakness, and seek immediate medical attention if these occur.

Misbadi is contraindicated in individuals with active major bleeding, severe uncontrolled hypertension, or known hypersensitivity to dabigatran etexilate. It should also be avoided in patients with severe renal impairment (creatinine clearance <30 mL/min) and in those who have had a recent intracranial hemorrhage or are scheduled for certain high‑risk surgeries without appropriate interruption.